New drug CIT-013 aims to calm painful skin flares
NCT ID NCT06993233
First seen Nov 20, 2025 · Last updated May 20, 2026 · Updated 19 times
Summary
This study tests a new drug called CIT-013 for people with hidradenitis suppurativa (HS), a painful skin condition. About 96 adults with moderate to severe HS will receive either a low or high dose of CIT-013 or a placebo every two weeks for 12 weeks. The main goal is to see if CIT-013 reduces skin abscesses and inflammation better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CA-01
RECRUITINGBarrie, Canada
Contact
-
CA-02
RECRUITINGLondon, Canada
Contact
-
CA-03
RECRUITINGWinnipeg, Canada
Contact
-
CA-04
RECRUITINGNewmarket, Canada
Contact
-
CA-05
RECRUITINGCalgary, Canada
Contact
-
DE-01
RECRUITINGBochum, Germany
Contact
-
DE-02
RECRUITINGFrankfurt, Germany
Contact
-
DE-03
NOT_YET_RECRUITINGOldenburg, Germany
Contact
-
DE-04
RECRUITINGDresden, Germany
Contact
-
DE-06
RECRUITINGBad Bentheim, Germany
Contact
-
DE-08
RECRUITINGKiel, Germany
Contact
-
ES-01
NOT_YET_RECRUITINGValencia, Spain
Contact
-
ES-02
NOT_YET_RECRUITINGSantiago de Compostela, Spain
Contact
-
ES-03
NOT_YET_RECRUITINGSeville, Spain
Contact
-
ES-04
NOT_YET_RECRUITINGMadrid, Spain
Contact
-
ES-05
NOT_YET_RECRUITINGBarcelona, Spain
Contact
-
Erasmus UMC
RECRUITINGRotterdam, Netherlands
Contact
-
GB-02
NOT_YET_RECRUITINGCardiff, United Kingdom
Contact
-
GB-04
RECRUITINGLondon, United Kingdom
Contact
-
GB-05
RECRUITINGChester, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
PL-01
RECRUITINGRzeszów, Poland
Contact
-
PL-02
NOT_YET_RECRUITINGLodz, Poland
Contact
-
PL-03
RECRUITINGKatowice, Poland
Contact
-
PL-05
RECRUITINGWroclaw, Poland
Contact
Conditions
Explore the condition pages connected to this study.